title: Establishment of orally-administered Lactobacillus gasseri SBT2055SR in the gastrointestinal tract of humans and its influence on intestinal microflora and metabolism.
abstract: OBJECTIVE
  To investigate the fate of a streptomycin-rifampicin-resistant variant of Lactobacillus gasseri SBT2055 (LG2055SR) and the influence of its oral administration on the composition and metabolism of the intestinal microflora.
  
  
  RESULTS
  Intestinal passage of LG2055SR was monitored by a combination of selection with antibiotics and identification by a randomly amplified polymorphic DNA (RAPD)-PCR METHOD: Composition of intestinal microflora was analysed by the method developed by Mitsuoka et al. (1965, 1974). Establishment of orally-administered LG2055SR in the human intestine was confirmed in this study. LG2055SR ingestion specifically lowered faecal populations of Staphylococcus and faecal contents of p-cresol.
  
  
  CONCLUSIONS
  LG2055SR and its parent strain, LG2055, are considered to be appropriate candidates for probiotics.
  
  
  CONCLUSIONS
  It is clarified that LG2055SR has the ability to establish in the human gastrointestinal tract and alters the composition and metabolism of the intestinal microflora and physical characteristics of faeces.
authors: Technology and Research Institute, Snow Brand Milk Products Co., Ltd, Kawagoe, Saitama, Japan. ht4s-fjwr@asahi-net.or.jp
authors: S
authors: S
authors: Fujiwara
authors: Y
authors: Y
authors: Seto
authors: A
authors: A
authors: Kimura
authors: H
authors: H
authors: Hashiba
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D004064:Digestive System / Q000382:microbiology*; D004352:Drug Resistance, Microbial; D005243:Feces / Q000737:chemistry / Q000201:enzymology / Q000382:microbiology; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000382:microbiology; D007778:Lactobacillus / Q000187:drug effects / Q000254:growth & development*; D008297:Male; D019936:Probiotics / Q000008:administration & dosage*; D012293:Rifampin / Q000494:pharmacology; D013307:Streptomycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D012293:Rifampin; D013307:Streptomycin